Funded Biotechnology Startups in Pittsburgh
Pittsburgh's biotechnology sector has generated at least 12 disclosed funding rounds between November 2022 and October 2025, spanning early seed-stage clos…
Pittsburgh's biotechnology sector has generated at least 12 disclosed funding rounds between November 2022 and October 2025, spanning early seed-stage closes and a $160M raise by Krystal Biotech in May 2023 — the largest in this dataset by a wide margin. Peptilogics' $78M Series B in October 2025 is the most recent labeled institutional round, while companies like Novasenta ($15M, February 2024) and Mindstate Design Labs ($13M, November 2024) represent the mid-tier of recent activity.
Nine of the twelve rounds carry a "Series Unknown" classification, which is consistent with convertible notes, SAFEs, and undisclosed bridge financing common in university-adjacent biotech hubs. Pittsburgh's cluster draws on research ties to the University of Pittsburgh and Carnegie Mellon, and the company mix reflects that: LyGenesis (organ regeneration, Series A, $19M), Noveome Biotherapeutics (Series E, $21M), and Ocean Genomics (undisclosed amount) each represent distinct therapeutic and platform bets. Round sizes outside the two outliers cluster tightly between $2M and $21M.
Most recent rounds
12 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these Pittsburgh biotech companies?
Krystal Biotech raised the largest round at $160M (May 2023), followed by Peptilogics at $78M in a Series B closed October 2025. After those two, the next largest are Noveome Biotherapeutics at $21M (Series E, August 2023) and LyGenesis at $19M (Series A, October 2023).
How recent is the funding activity in this segment?
The most recent round shown is Peptilogics' $78M Series B from October 2025. Activity has been consistent across the period, with at least one close per quarter from late 2022 through early 2025, and Lipella Pharmaceuticals logging a $4M raise in March 2025.
What round stages appear most often in this data?
The majority of rounds are classified as Series Unknown — 9 of the 12 rows carry that label. Named stages include one Series A (LyGenesis), one Series B (Peptilogics), and one Series E (Noveome Biotherapeutics). The high proportion of undisclosed stage types is typical of smaller or bridge financings in early-stage biotech clusters.
Which companies raised smaller rounds that might still be early sales targets?
CytoAgents ($2M, September 2024), Carmell Therapeutics ($3M, April 2024), LifeX Labs ($2M, November 2023), and Cognition Therapeutics ($6M, November 2022) all raised sub-$10M rounds, suggesting early-stage operations with near-term vendor and partnership needs.
Is Pittsburgh biotech activity concentrated in any particular therapeutic focus?
The company names point to several distinct areas: gene therapy and genomics (Krystal Biotech, Ocean Genomics), regenerative and cell-based approaches (LyGenesis, Noveome Biotherapeutics, Carmell Therapeutics), neuroscience and cognition (Cognition Therapeutics, Mindstate Design Labs), and immuno-oncology (Novasenta, CytoAgents). No single focus dominates the 12 companies shown.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.